title: [Is the cytoreductive nephrectomy still necessary in case of metastases?].
abstract: Cytoredutive nephrectomy is a component of metastatic renal cell carcinoma management. This procedure can induce a spontaneous regression of metastases in a small number of cases. It increases the overall survival of correctly selected patients treated with immunotherapy. However, we still do not know if this benefit remains for patient treated with targeted therapies. In the three main prospective randomized studies evaluating targeted therapies, the majority of included patients have had prior nephrectomy. However, this surgical procedure is not without risk and could delay initiation of medical treatment. Age of patient, comorbidities, histologic pattern and surgical difficulties should be taken into account. Until results of prospective studies, the cytoreductive nephrectomy should be still considered as component of the treatment of metastatic renal cell carcinoma.
authors.affiliation: Service d'urologie, Hôpital Foch, Rue Worth, Suresnes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: G
authors.initials: G
authors.lastname: Pignot
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009362:Neoplasm Metastasis; D009392:Nephrectomy